BIOMAT Database Logo BIOMAT Database Logo

Gene and protein expression profiling during differentiation of neuroblastoma cells triggered by 13-cis retinoic acid. 2003

Yuki Yuza, and Miyuki Agawa, and Masaharu Matsuzaki, and Hisashi Yamada, and Mitsuyoshi Urashima
Department of Pediatrics, Jikei University School of Medicine, Tokyo, Japan.

OBJECTIVE The precise changes in RNA and protein expression that accompany neuroblastoma differentiation remain unknown. The authors used microarray technologies to screen molecules associated with the differentiation of neuroblastoma (NB) cells induced by 13-cis retinoic acid. METHODS The authors quantified the expression of 2,061 RNA transcripts related to oncogenesis and of 380 proteins expressed in SK-N-SH and CHP-134 NB cell lines in the presence or absence of 13-cis retinoic acid. RESULTS Hierarchical clustering captured gene expression altered during neuroblastoma differentiation induced by 13-cis retinoic acid. Several genes were further abstracted based on P values below 0.0017 or protein chips observed in both NB cell lines. The altered expressions of gene products revealed by both DNA and protein chips were in agreement. The expressions of N-myc, cyclin D3, and Wnt10B were downregulated, whereas those of retinoblastoma (RB) and related genes (p107, RB2/p130, p300/CBP, E2F-1, DP-1) as well as others were upregulated. CONCLUSIONS These results suggest that microarray technology can screen for genes that are important in neuroblastoma differentiation.

UI MeSH Term Description Entries
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D009447 Neuroblastoma A common neoplasm of early childhood arising from neural crest cells in the sympathetic nervous system, and characterized by diverse clinical behavior, ranging from spontaneous remission to rapid metastatic progression and death. This tumor is the most common intraabdominal malignancy of childhood, but it may also arise from thorax, neck, or rarely occur in the central nervous system. Histologic features include uniform round cells with hyperchromatic nuclei arranged in nests and separated by fibrovascular septa. Neuroblastomas may be associated with the opsoclonus-myoclonus syndrome. (From DeVita et al., Cancer: Principles and Practice of Oncology, 5th ed, pp2099-2101; Curr Opin Oncol 1998 Jan;10(1):43-51) Neuroblastomas
D002454 Cell Differentiation Progressive restriction of the developmental potential and increasing specialization of function that leads to the formation of specialized cells, tissues, and organs. Differentiation, Cell,Cell Differentiations,Differentiations, Cell
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D012334 RNA, Neoplasm RNA present in neoplastic tissue. Neoplasm RNA
D014407 Tumor Cells, Cultured Cells grown in vitro from neoplastic tissue. If they can be established as a TUMOR CELL LINE, they can be propagated in cell culture indefinitely. Cultured Tumor Cells,Neoplastic Cells, Cultured,Cultured Neoplastic Cells,Cell, Cultured Neoplastic,Cell, Cultured Tumor,Cells, Cultured Neoplastic,Cells, Cultured Tumor,Cultured Neoplastic Cell,Cultured Tumor Cell,Neoplastic Cell, Cultured,Tumor Cell, Cultured
D015474 Isotretinoin A topical dermatologic agent that is used in the treatment of ACNE VULGARIS and several other skin diseases. The drug has teratogenic and other adverse effects. 13-cis-Retinoic Acid,Accutane,Isotretinoin Zinc Salt, 13-cis-Isomer,Ro 4-3780,Roaccutane,13 cis Retinoic Acid,Isotretinoin Zinc Salt, 13 cis Isomer,Ro 4 3780,Ro 43780
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic

Related Publications

Yuki Yuza, and Miyuki Agawa, and Masaharu Matsuzaki, and Hisashi Yamada, and Mitsuyoshi Urashima
Human neuroblastoma cells and 13-cis-retinoic acid.
January 1985, Journal of neuro-oncology,
Yuki Yuza, and Miyuki Agawa, and Masaharu Matsuzaki, and Hisashi Yamada, and Mitsuyoshi Urashima
Spontaneous fractures during 13-cis retinoic acid therapy for neuroblastoma.
May 2023, Pediatric blood & cancer,
Yuki Yuza, and Miyuki Agawa, and Masaharu Matsuzaki, and Hisashi Yamada, and Mitsuyoshi Urashima
Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastoma.
December 2014, British journal of pharmacology,
Yuki Yuza, and Miyuki Agawa, and Masaharu Matsuzaki, and Hisashi Yamada, and Mitsuyoshi Urashima
Bottom up proteomics reveals novel differentiation proteins in neuroblastoma cells treated with 13-cis retinoic acid.
October 2019, Journal of proteomics,
Yuki Yuza, and Miyuki Agawa, and Masaharu Matsuzaki, and Hisashi Yamada, and Mitsuyoshi Urashima
MicroRNA mediates DNA demethylation events triggered by retinoic acid during neuroblastoma cell differentiation.
October 2010, Cancer research,
Yuki Yuza, and Miyuki Agawa, and Masaharu Matsuzaki, and Hisashi Yamada, and Mitsuyoshi Urashima
Hypercalcemia induced by 13 cis-retinoic acid in patients with neuroblastoma.
April 2008, Pediatrics international : official journal of the Japan Pediatric Society,
Yuki Yuza, and Miyuki Agawa, and Masaharu Matsuzaki, and Hisashi Yamada, and Mitsuyoshi Urashima
Gene expression and neuroblastoma cell differentiation in response to retinoic acid: differential effects of 9-cis and all-trans retinoic acid.
January 1995, European journal of cancer (Oxford, England : 1990),
Yuki Yuza, and Miyuki Agawa, and Masaharu Matsuzaki, and Hisashi Yamada, and Mitsuyoshi Urashima
13 Cis-retinoic acid mediates apoptosis in Dalton's lymphoma ascites cells by regulating gene expression.
January 2007, Journal of basic and clinical physiology and pharmacology,
Yuki Yuza, and Miyuki Agawa, and Masaharu Matsuzaki, and Hisashi Yamada, and Mitsuyoshi Urashima
9-cis-retinoic acid selectively activates the cellular retinoic acid binding protein-II gene in human neuroblastoma cells.
June 1995, Archives of biochemistry and biophysics,
Yuki Yuza, and Miyuki Agawa, and Masaharu Matsuzaki, and Hisashi Yamada, and Mitsuyoshi Urashima
Hypercalcemia induced by 13-cis-retinoic acid in a patient with neuroblastoma.
May 2002, Pharmacotherapy,
Copied contents to your clipboard!